Michele H. Mokrzycki

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mokrzycki_Michele_MD-2.jpg

First Name

Michele

Last Name

Mokrzycki

NPI

1215048822

Faculty ID

4647

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Mokrzycki&nbsp;is a graduate of&nbsp;Boston College (B.S., 1983),&nbsp;and the University of Vermont College of Medicine (M.D., 1987) and received a&nbsp;Masters&nbsp;of Science&nbsp;in Clinical Research from the Albert Einstein College of Medicine (M.S. 2000). She&nbsp;completed&nbsp;both an&nbsp;Internal&nbsp;Medicine Residency and Clinical Nephrology Fellowship at the University&nbsp;of&nbsp;Connecticut Health Science Center in Farmington, CT. &nbsp;Dr Mokrzycki has been on faculty at the Albert Einstein College of Medicine since 1992, where she is a Professor of Medicine in the Division of Nephrology. &nbsp;She is a full time clinical nephrologist at the Montefiore Medical Center, Moses Campus.</p>
<p>Dr Mokrzycki's&nbsp;research interests have focused primarily on hemodialysis vascular access related complications, specifically,&nbsp;complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. &nbsp;</p>
<p>She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. &nbsp;</p>
<p>Dr Mokrzycki&nbsp;served on the Program Committee Member for the National Kidney Foundation (NKF)&nbsp;for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA)&nbsp;for&nbsp;5 years, which is&nbsp;held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions&nbsp;at the American Society of Nephrology (ASN),&nbsp;National Kidney Foundation (NKF), the Vascular Access Society (VAS), Hemodialysis University (HDU), Annual Dialysis Conference (ADC), the&nbsp;American Society of Diagnostic and Interventional Nephrology (ASDIN), and the VEITH symposium.</p>
<p>Dr Mokrzycki served on the Catheter Endpoints Workgroup of the Kidney Health Initiative (KHI), formed by the American Society of Nephrology,the FDA and other stakeholders in End Stage Kidney Disease Innovation. &nbsp;Dr Mokrzycki currently serves as the Chair of the Vascular Accesss Outcomes Workgroup, a subgroup of the Nephrologists Transforming Dialysis Safety Initiative (NTDS), which is a collaboration between the American Society of Nephrology and the Centers for Disease Control.&nbsp;</p>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Dr. Mokrzycki is board certified in Nephrology and is a Fellow of the American Society of Nephrology. Clinical interests include Glomerular Diseases, Acute and Chronic Kidney Diseases, Hypertension, Kidney Stones, Renal Cystic Diseases, Dialysis, and Vascular Access for Hemodialysis.</p>

Research Focus

<p>Dr. Mokrzycki completed a Masters Program in Clinical Research at the Albert Einstein College of Medicine. The author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications.</p>

Elsevier Profile

Selected Publications

<ol>
<li><strong>Mokrzycki MH</strong>, Yamase H, Kohn OF.&nbsp; Renal malacoplakia with papillary necrosis and renal failure. Am J Kidney Dis 19:587-91, 1992.</li>
<li><strong>Mokrzycki MH</strong>, Kaplan AA.&nbsp; Therapeutic Plasma Exchange: Complications and management.&nbsp; Am J Kidney Dis 23:817-27, 1994.</li>
<li><strong>Mokrzycki MH</strong>, Rickles F, Kaplan AA, Kohn OF.&nbsp; Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange.&nbsp; Blood Purif 13:271-82, 1995.</li>
<li>Posner L, <strong>Mokrzycki MH</strong>. Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.&nbsp; Am J Nephrol 16:339-43,1996.</li>
<li>Kerr A, Spector J, <strong>Mokrzycki MH</strong>, Blau S, Simon R.&nbsp; V asodilator provocation of occult urinar y tract hemorrhage. J Trauma 40:152-4, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Kaplan AA.&nbsp; Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 7:1-5, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Harris C, May H, Laut J, Palmisano J.&nbsp; Lactic acidosis associated with stavudine (d4T): Report of 5 cases. Clin Inf Dis 30:198-200, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Schroppel B, von Gersdorff G, Rush H, Zdunek M, Feingold R.&nbsp; Tunneled cuffed catheter associated infections in hemodialysis patients seropositive for the human immunodeficiency virus.&nbsp; J Am Soc Nephrol 11:2122-2127, 2000.</li>
<li>Barisoni L, <strong>Mokrzycki MH</strong>, Sablay L, Nagata M, Yamase H, Mundel P.&nbsp; Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies.&nbsp; Kidney Int 58:137-143, 2000.</li>
<li>Zdunek MP, Mitra A, <strong>Mokrzycki MH</strong>.&nbsp; Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance.&nbsp; Am J Kidney Dis 36:177-183, 2000.</li>
<li>Solomon N, <strong>Mokrzycki MH</strong>.&nbsp; Levofloxacin-associated allergic interstitial nephritis.&nbsp; Clin Nephrol 54:356, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO.&nbsp; A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59:1935-1942, 2001.</li>
<li>Swiatecka-Urban A, <strong>Mokrzycki MH</strong>, Kaskel F, Da Silva F, Denamur E.&nbsp; Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.&nbsp;&nbsp; Pediatr Nephrol 16:627-630, 2001.</li>
<li><strong>Mokrzycki MH,</strong> Singhal A.&nbsp; Cost-Effectiveness of Three Strategies of Managing Tunneled-Cuffed Hemodialysis Catheters (TCC) in Clinically Mild or Asymptomatic Bacteremias.&nbsp; Nephrol Dial Transpl 17(12): 2196-203, 2002.</li>
<li>Negulescu O, Coco M, Croll J, <strong>Mokrzycki MH</strong>. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 59(1):40-6, 2003.</li>
<li>Golestaneh L, Laut J, Rosenberg S, Zhang M, <strong>Mokrzycki MH</strong>.&nbsp; Favourable outcomes in episodes of Pseudomonas bacteremia when associated with tunneled cuffed catheters (TCC) in chronic hemodialysis patients.&nbsp; Nephrol Dial Transplant. May;21(5):1328-33,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO.&nbsp; Tunneled Hemodialysis Catheter Bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 21(4):1024-31,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Golestaneh L, Laut J, Rosenberg SO.A randomized controlled trial comparing two management models for the treatment of tunneled cuffed catheter (TCC) bacteremia: A collaborative team model versus usual physician-managed care. Am J Kidney Dis 48(4):587-95, 2006.</li>
<li>McKenzie LM, Hendrickson, SL, Briggs WA, Dart RA, Korbet SM, <strong>Mokrzycki MH</strong>, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA.&nbsp; NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 18(11): 2987-95, 2007</li>
<li><strong>Mokrzycki MH.</strong>&nbsp; Use of prophylactic topical or intraluminal antibiotics for hemodialysis catheters. Nat Clin Pract Nephrol 4(9):478-9, 2008.</li>
<li>Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, <strong>Mokrzycki MH</strong>, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 40 (10):1175-84, 2008.</li>
<li>Sachdeva M, Bitzer M, <strong>Mokrzycki MH</strong>. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study.&nbsp; J Vascular Access 10(3):174-179, 2009.</li>
<li>Golestaneh L, Gofran A, <strong>Mokrzycki MH</strong>, Chen JL.&nbsp; Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing.&nbsp; Clin Neph 72 (4):286-291.</li>
<li>Okafor C, Ward DM, <strong>Mokrzycki MH,</strong> Weinstein R, Clark P, Balogun RA.&nbsp; Introduciton and overview of therapeutic apheresis.&nbsp; J Clin Apheresis, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Advances in Hemodialysis Catheter-related Infection.&nbsp; U.S. Nephrol, 2010.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Traditional and nontraditional strategies to optimize catheter function: <em>Go with more flow.</em> Kidney Int, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Update 2010: Catheter-related Infection in Hemodialysis Patients. Kidney Int. 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Prevention and management of catheter-related infection in hemodialysis patients.&nbsp; Kidney Int. 2010;79(6):587-98.</li>
<li><strong>Mokrzycki MH</strong>, Balogun RA.&nbsp; Therapeutic Apheresis: a review of complications and recommendations for prevention and management.&nbsp; J Clin Apher 2011:26(5):243-8.</li>
<li>Lee T, <strong>Mokrzycki MH</strong>, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial 2011;24(5):515-24.</li>
<li>Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, <strong>Mokrzycki MH</strong>, Kimmel PL, Limous S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollack M, Winkler CA.&nbsp; APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011;22(11):2129-37.</li>
<li>Sachdeva M, Hung A, Kovalchuk O, Bitzer M, <strong>Mokrzycki MH</strong>. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Int J Nephrol Volume 2012; (2012) Article ID: 917465.</li>
<li>Lee T, Lok C, Vazquez M, Moist L, Maya I, <strong>Mokrzycki M</strong>.&nbsp; Minimizing hemodialysis catheter dysfunction: An ounce of prevention.&nbsp; Int J Nephrol; Volume 2012 (2012), Article ID: 170857.</li>
<li>Golestaneh L, <strong>Mokrzycki MH</strong>. Vascular Access in Therapeutic Apheresis: Update 2013.&nbsp; J Clin Apheresis. 2013: 28(1):64-72.</li>
<li>Nica A, Lok CE, Harris J, Lee TC, <strong>Mokrzycki MH</strong>, Maya ID, Vazquez MA, Xi W, Moist LM; From the North American Vascular Access Consortium (NAVAC). Understanding Surgical Preference and Practice in Hemodialysis Vascular Access creation. Semin Dial. 2013:26(4):520-526.</li>
<li>Bhatt DL, Kandzari DE, O&rsquo;Neill WW, D&rsquo;Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370 (15):1393-1401.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Optimizing central venous catheter primary prevention trials in hemodialysis patients. Am. J.Kidney Dis. 2015;66(6):939-941.</li>
<li>Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson P, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova , Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, <strong>Mokrzycki MH</strong>, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol. 2016;11 (1):81-89.</li>
<li>Johns, TS, <strong>Mokrzycki MH</strong>. Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia. Clin J Am Soc Nephrol 2016; 11.</li>
<li>Liang E, Rodriguez M, Mueller M, Abramowitz MK, <strong>Mokrzycki&nbsp; MH</strong>. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature. J. Clin. Nephrol. Renal Care. 2016, 2(1): 10-16.</li>
<li>Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand D,&nbsp; Easom A, Mermel L, <strong>Mokrzycki MH</strong>, Patel PR, Roy-Chaudhury P, Shenoy S, Valentini RP, Wasse H.&nbsp; Moving Points in Nephrology: Recommended Clinical Trial Endpoints for Hemodialysis Catheters. Clin J Am Soc Nephrol. 2017</li>
<li>&nbsp;Golestaneh L, <strong>Mokrzycki MH</strong>. Prevention of Hemodialysis Catheters Infections: Ointments, Dressings, Locks and Catheter Hub Devices. Hemodial Int. Nov 2018</li>
<li>Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, <strong>Mokrzycki M</strong>, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019 Jul;20(7):915-927</li>
<li>Fisher M, Golestaneh L, Allon M, <span style="font-family: 'Times New Roman', serif; font-size: 12pt;">&nbsp;</span><span style="font-family: 'Times New Roman', serif; font-size: 12pt;">Abreo K, </span><strong style="font-family: 'Times New Roman', serif; font-size: 12pt;">Mokrzycki MH.&nbsp;</strong>Preventing Central Vein Catheter Associated Bloodstream Infections in Hemodialysis: Review of Current Evidence-Based Strategies and Novel Therapies. <span style="font-size: 12pt; font-family: 'Times New Roman', serif;">Clin J Am Soc Nephrol 2020;15:132-151</span></li>
<li><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Vachharajani T , Wong L, Niyyar VD, Abreo KD, <strong>Mokrzycki MH</strong>, for the Vascular Access Workgroup of the Nephrologists Transforming Dialysis Safety Initiative of the American Society of Nephrology. Buttonhole cannulation of arteriovenous fistulas in the United States. Kidney360. 2020 </span></li>
<li><strong style="text-indent: -0.25in; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-size: 12pt;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;"> and Coco M. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States. Kidney360. 2020:1(4);273-278.</span></li>
<li><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Fisher M, Yunes M, <strong>Mokrzycki MH</strong>, Golestaneh L, Alahiri E, Coco M. &ldquo;Chronic Hemodialysis Patients Hospitalized with COVID-19 &ndash; Short-term Outcomes in Bronx, New York&rdquo;. Kidney360 June 2020</span>1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></li>
<li><strong style="text-indent: -0.25in;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">, Leigh KA, Kliger AS, Niyyar VD, Bren Asp V, Golestaneh L, Taylor Q, Novosad SA. Implementation of an Electronic Catheter Checklist in Outpatient Hemodialysis Facilities: Results of a Pilot Quality Improvement Project. Kidney360&nbsp; April 2021, 2(4) 684-694</span>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;">&nbsp;</p>
</li>
</ol>
<p><em><strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Book Chapter</span></strong></em></p>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp; &nbsp; &nbsp;</span></span></span><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Fisher M, <strong style="mso-bidi-font-weight: normal;">Mokrzycki MH.</strong> Infectious complications in vascular access. Handbook of Dialysis. Nissenson: Handbook of Dialysis Therapy, 6e.</span> <span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Elsevir (In press, 2021)</span></p>

EMR ID

3774

Biography

<p>Michele H. Mokrzycki, MD, MS, is an attending nephrologist and Professor, Medicine at Montefiore Einstein. Dr. Mokrzycki&rsquo;s clinical interests include glomerular diseases, acute and chronic kidney diseases, hypertension, kidney stones, renal cystic diseases, dialysis and vascular access for hemodialysis.</p><p>After earning her Bachelor of Science from Boston College in 1983, Dr. Morkrzycki pursued her Doctor of Medicine at University of Vermont College of Medicine, earning the degree in 1987. She performed her postdoctoral training at University of Connecticut Health Center, completing her residency in internal medicine in 1990 and her fellowship in clinical nephrology in 1992. Dr. Mokrzycki later pursued additional education, completing her Master of Science in clinical research at Einstein in 2000.</p><p>Author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications. She is on the editorial board for <em>Kidney360</em>, and is an invited reviewer for several publications including the <em>Journal of the American Society of Nephrology, Hemodialysis International</em> and the <em>Journal of Vascular Access.</em></p><p>Dr. Mokrzycki is board certified in Nephrology. She is a Fellow of the American Society of Nephrology and a member of several professional societies including the National Kidney Foundation, New York Society of Nephrology and the North American Vascular Access Consortium. In 2020, she was recognized as Reviewer of the Year by <em>Kidney360</em>.</p>

Is Open Scheduling

On

Kara L. Watts

https://assets.montefioreeinstein.org/profiles/images/Watts_Kara_MD_2x.jpg

First Name

Kara

Last Name

Watts

NPI

1215222856

Faculty ID

15490

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

56078

Biography

<p>Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.</p><p>Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.</p><p>Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.</p>

Is Open Scheduling

On

Asli S. Sucu

https://assets.montefioreeinstein.org/profiles/images/16076-asli-sucu.jpg

First Name

Asli

Last Name

Sucu

NPI

1477815934

Faculty ID

16076

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55869

Is Open Scheduling

Off

Deep Sharma

https://assets.montefioreeinstein.org/profiles/images/physphoto/Sharma_Deep_MD_420x504.jpg

First Name

Deep

Last Name

Sharma

NPI

1578759338

Faculty ID

12095

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Kidney stones, Glomerular diseases, Chronic kidney disease, End Stage renal disease&nbsp;

Research Focus

Treatment for anemia in patients with chronic kidney disease and end stage renal disease on dialysis

Elsevier Profile

EMR ID

5356

Biography

<p></p>Deep Sharma, MBBS, earned his medical degree from University College of Medical Sciences in Delhi, India. He then completed his residency and chief residency at Good Samaritan Hospital, Baltimore followed by his nephrology fellowship at Montefiore Medical Center where he joined as faculty after completion of his fellowship. He is board certified in Medicine and Nephrology and is a member of the American Society of Nephrology. Dr. Sharma is the clinical director of Nephrology for Weiler Hospital and the medical director of Fresenius Eastchester and Fresenius Freedom Center of the Bronx that treats patients who need dialysis for End Stage Kidney disease, both incenter and at home. With the help of his Urology colleagues, he helped establish the kidney stone program at Montefiore and that sees patients with kidneys stones in the clinic. Dr. Sharma has been involved in clinical studies looking at muscle mass in patients with kidney disease and the treatment of anemia in patients with chronic kidney disease and dialysis.<p></p>

Visit Type ID

2541

Is Open Scheduling

On

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Michael J. Ross

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ross_Michael_MD_420x504.jpg

First Name

Michael

Last Name

Ross

NPI

1851321368

Faculty ID

15329

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="p1">&nbsp;</p>
<p class="p1">The major focus of research in the Ross laboratory is to identify novel mechanisms of kidney injury occurring in HIV-positive persons and his laboratory uses in vitro and murine models to generate new strategies to prevent and treat kidney diseases. Dr. Ross also works with members of the International Network for Strategic Initiatives in Global HIV Treatment (INSIGHT) to perform research on kidney disease in the context of large international HIV treatment trials.</p>
<p class="p1"><strong><span style="text-decoration: underline;">Ongoing NIH-funded projects:</span></strong></p>
<p class="p1"><strong>Mechanisms by which antiretroviral medications protect kidneys from HIV-induced injury:</strong></p>
<p class="p1">Though combination antiretroviral therapy (cART) is efficacious in preventing and treating HIV-associated nephropathy (HIVAN), the mechanisms by which these medications protect the kidney from the deleterious effects of HIV are poorly understood.&nbsp;&nbsp;We are performing studies using transgenic animal models and molecular and genomic techniques to identify novel pathways by which ART protect the kidneys from HIV.&nbsp;&nbsp;Moreover, we have exciting data suggesting that these medications may protect kidneys from non-viral mediated forms of kidney injury, including diabetic kidney disease.</p>
<p class="p1"><strong>The role of APOL1 polymorphisms in promoting HIV-induced kidney injury:</strong></p>
<p class="p1">Polymorphisms in the APOL1 gene account for most of the excess risk of African-Americans to non-diabetic kidney disease and HIV-associated kidney disease in particular. In our studies, we are using genetically modified human kidney cells to perform innovative proteomic, and genomic studies to identify novel mechanisms by APOL1 genetic variants predispose to HIV-induced kidney injury.&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p><span style="color:black;">Chronic kidney disease, diabetic kidney disease, acute kidney injury, glomerular diseases, cystic kidney diseases, electrolyte disorders, hypertension, HIV and other virus-related kidney diseases.</span></p>

Research Focus

<p><span style="color:black;">The primary focus of Dr. Ross' research is to identify mechanisms by which HIV and immune dysregulation cause kidney disease and to identify new approaches to prevent and treat kidney disease. Dr. Ross is also involved in clinical studies to determine mechanisms of diabetic kidney injury and to test the effectiveness of novel treatments for chronic kidney diseases.</span></p>

Elsevier Profile

Selected Publications

<p><span style="text-decoration: underline;"><strong>Most relevant publicatiion in past 10 years:</strong></span></p>
<p>*Mocroft, A., Wyatt, C., Szczech, L., Neuhaus, J., El-Sadr, W., Tracy, R., Kuller, L., Shlipak, M., Angus, B., Klinker, H., and <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>. Interruption of antiretroviral therapy is associated with increased plasma cystatin C: Results from the SMART Study. <em>AIDS</em>. 23, 71-82. 2009.</p>
<p>*Snyder A, Alsauskas Z, Gong P, Rosenstiel P, Klotman M, Klotman P, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>: FAT10: a novel mediator of Vpr-induced apoptosis in HIV-associated nephropathy. <em>J Virol</em>. 83;11983-11988. 2009.</p>
<p>*Gong, P., Canaan, A., Wang, B., Leventhal, S., Snyder, A., Nair, V., Cohen, C. D., Kretzler, M., D'Agati, V., Weissman, S., and <strong><span style="text-decoration: underline;">Ross, M. J</span></strong>. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J Am Soc Nephrol. 21:316. 2009.</p>
<p>Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan J, Barley K, He C, Klotman M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Klotman PE. HIV-1 viral protein r induces ERK and caspase-8 dependent apoptosis in renal tubular epithelial cells. <em>AIDS</em>, 24:1107-1119. 2010.</p>
<p>Neuhaus, J., Jacobs, D.R., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L., Pett, S.L., Ristola, M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Shlipak, M., Tracy, R., and Neaton, J.D. Markers of Inflammation, Coagulation and Renal Function Are Elevated in Adults with HIV Infection. <em>J Infect Dis</em>. 201:1788-1795. 2010.</p>
<p>Chen, P., Chen, B.K., Mosoian, A., Hays, T., <strong><span style="text-decoration: underline;">Ross, M.J</span></strong>., Klotman, P.E., and Klotman, M.E. Virological Synapses Allow HIV-1 Uptake and Gene Expression in Renal Tubular Epithelial Cells. J Am Soc Nephrol. &nbsp;22(3): 496-507. 2011.</p>
<p>Leventhal, J.S., Alsauskas, Z., Snyder, A., Gong, P., Wang, B., D&rsquo;Agati, V., and <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong> Renal HIV Expression Is Unaffected by Serum LPS Levels in an HIV Transgenic Mouse Model of LPS Induced Kidney Injury. <em>PLoS One.</em> <strong>6</strong>:e20688. 2011.</p>
<p>Papeta, N., Kiryluk, K., Patel, A., Sterken, R., Kacak, N., Snyder, H.J., Imus, P.H., Mhatre, A.N., Lawani, A.K., Julian, B.A., Wyatt, R.J., Novak, J., Wyatt, C.M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Winston, J.A., Klotman, M.E., Cohen, D.J., Appel, G.B., D&rsquo;Agati, V.D., Klotman, P.E., and Gharavi, A.G. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. <em>J Am Soc Nephrol.</em> 22:1991-1996. 2011.</p>
<p>Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>*, Wyatt CM*: Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE 7:e40245, (*co-senior authors). 2012.</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD: Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis 2013.</p>
<p>Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Crum-Cianflone NF: Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med 14:65-76, 2013</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 1;207(9):1359-69. 2013.</p>
<p>Lucas, G., Cozzi-Lepri, A., Wyatt, C., Post, F., Bormann, A., Crum-Cianflone, N., and <strong><span style="text-decoration: underline;">Ross, M</span></strong>. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 15:116-123. PubMed PMID: 24024499. 2014.</p>
<p>Lucas, GM, <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>, Stock, PG, Shlipak, MG, Wyatt, CM, Gupta, SK, Atta, MG, Wools-Kaloustian, KK, Pham, PA, Bruggeman, LA, Lennox, JL, Ray, PE, and Kalayjian, RC. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update By the HIV Medicine Association of the Infectious Diseases Society of America. <em>Clin Infect Dis</em>; 59(9), e96-e138. 2014.</p>
<p>Ryom, L., Mocroft, A., Kirk, O., <strong><span style="text-decoration: underline;">Ross, M</span></strong>., Reiss, P., Fux, C. A., Morlat, P., Moranne, O., Smith, C., El-Sadr, W., Law, M., and Lundgren, J. D. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 28, 187-199. 2014.</p>
<p>Mocroft A, Lundgren J, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events&nbsp; (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study&nbsp; group. A clinically useful risk-score for chronic kidney disease in HIV infection. J Int AIDS Soc ;17(4 Suppl 3):19514.. PMID: 25394023; PMCID: PMC4224906. 2014.</p>
<p>Leventhal, J.S., He, J.C., and <strong><span style="text-decoration: underline;">Ross, M.J</span></strong><span style="text-decoration: underline;">.</span> Autophagy and Immune Response in Kidneys. <em>Semin Nephrol.</em> 34(1):53-61. 2014.</p>
<p><strong><span style="text-decoration: underline;">Ross, M. J.</span></strong> (2014). Advances in the pathogenesis of HIV-associated kidney diseases. <em>Kidney Int.</em> 86, 266-274. 2014.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. PMID: 25826420; PMCID: PMC4380415. 2015.</p>
<p>Wolf T, <strong><span style="text-decoration: underline;">Ross MJ*</span></strong>, and Davenport A. Minimizing risks associated with renal replacement therapy in patients with Ebola Virus Disease. <em>Kidney Int.</em> 2015. 87, 5-7. 2015.</p>
<p>Achhra AC, Mocroft A, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-na&iuml;ve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med;16 Suppl 1:55-63. PMID: 25711324; PMCID: PMC4341947. 2015.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 3:e23-32. 2016.</p>
<p>Leventhal JS, Ni J, Osmond M, Lee K, Gusella GL, Salem F, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal Tubular Epithelial Cell Cytokine Expression. PLoS One. 11(3):e0150001. 2016.</p>
<p>Ryom, L, Lundgren, JD, <strong><span style="text-decoration: underline;">Ross, M</span></strong>, Kirk, O, Law, M, Morlat, P, Smit, C, Fontas, E, Fux, CA, Hatleberg, CI, de Wit, S, Sabin, CA, Mocroft, A, D:A:D, SG. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. J Infect Dis. PMID: 27485357. 2016.</p>
<p>Ryom L, Mocroft A, Kirk O, Reiss P, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017 Mar 28. PMID: 28353536.</p>
<p>Nadkarni GN, Wyatt CM, Murphy B, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. APOL1: a case in point for replacing race with genetics. Kidney Int. 2017 Apr;91(4):768-770. PMID: 28314574.</p>
<p>Rednor SJ, <strong>Ross MJ</strong>. Molecular Mechanisms of Injury in HIV-Associated Nephropathy. Front Med (Lausanne). 2018; 5:177. PMID: 29930940 PMCID: PMC5999756</p>
<p><strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Coates PT. Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation. Kidney Int. 2018; 93:4-6, PMID: 29198467.</p>
<p><strong><span style="text-decoration: underline;">Ross MJ.</span></strong> New Insights into APOL1 and Kidney Disease in African Children and Brazilians Living With End-Stage Kidney Disease. Kidney Int Rep. 2019; 4:908-910 PMC6611947.</p>
<p>Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369. PubMed PMID: 31504669; PubMed Central PMCID: PMC6782100.</p>
<p>Gao X, Rosales A, Karttunen H, Bommana GM, Tandoh B, Yi Z, Habib Z, Agati V, Zhang W, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms. Sci Rep. 2019 Nov 1;9(1):15857. doi: 10.1038/s41598-019-52278-3. PubMed PMID: 31676833; PubMed Central PMCID: PMC6825220.</p>
<p>Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Sarov-Blat L, Steinbugler K, Susztak K. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney Int. 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020. PubMed PMID: 31901339.</p>
<div class="citation-text" data-citation-style="ama">Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. PMID: 32329975; PMCID: PMC7200055.</div>

EMR ID

1540

Biography

<p>Dr. Michael Ross received his MD degree at NYU and completed internal medicine residency training at Duke University, followed by Nephrology Fellowship training at the Icahn School of Medicine at Mount Sinai. While he was on the faculty in the Mount Sinai Division of Nephrology from 2001-17, he served as Nephrology Fellowship Program Director from 2004-2015. He became Chief of Nephrology at the James J. Peters VA Medical Center from 2014-2017, where he helped establish the only VA Kidney Transplant Program in the northeastern US. Dr. Ross became Chief of the Division of Nephrology at the Albert Einstein College of Medicine/Montefiore Medical Center in 2017 where he is currently Chief of Nephrology and Professor of Medicine and Developmental and Molecular Biology.&nbsp;</p><p>Dr. Ross has served in several national/international leadership roles for the American Society of Nephrology and other organizations, served as Deputy Editor of Kidney International, and is currently Nephrology Section Editor of the American College of Physicians Medical Knowledge and Self-Assessment Program. Dr. Ross was also the recipient of the 2021 American Society of Nephrology Distinguished Leader Award. The major focus of Dr. Ross&rsquo; research program is to identify novel mechanisms of HIV-induced kidney diseases and other forms of kidney injury. He is also site principal investigator of clinical and translational research studies of diabetic kidney disease and other kidney diseases.&nbsp;<br /></p>

Is Open Scheduling

Off

Erin L. Ohmann

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8ad52610-8315-11ed-bb08-39bbd9d39d57.jpg

First Name

Erin

Last Name

Ohmann

NPI

1548551781

Faculty ID

16467

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Clinical focus is general urology with a special interest in endourology and male and female voiding dysfunction.</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Ohmann is a frequent contributor to medical publications and abstracts in the area of benign urology, and her work has been published in several peer-reviewed publications.</span><quillbot-extension-portal></quillbot-extension-portal>

EMR ID

115672

Biography

<p>Erin Ohmann, MD, is an attending physician and Assistant Professor of Urology at Montefiore Einstein. Her clinical focus is general urology with a special interest in endourology and male and female voiding dysfunction. She specializes in treating conditions such as benign prostatic hypertrophy, urinary retention, urinary incontinence, overactive bladder, kidney stones, bladder stones, bladder cancer and prostate cancer.</p><p>After graduating from Cornell University with a Bachelor of Science degree, she received her medical degree from the University of Pittsburgh School of Medicine. While in medical school, she participated in the Doris Duke Clinical Research Program and earned a Master of Science in Clinical Research. Dr. Ohmann then completed surgical internship and urology residency at New York University Langone Medical Center.</p><p>Dr. Ohmann is a frequent contributor to medical publications and abstracts in the area of benign urology, and her work has been published in several peer-reviewed publications.</p><p>Dr. Ohmann is board certified in urology and is a fellow of the Jewish Healthcare Foundation Patient Safety. She is a member of the American Urological Association and Alpha Omega Alpha Honor Medical Society. She has received numerous awards and honors for her work.</p>

Is Open Scheduling

Off

Amanda C. North

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/ab0672f0-76a6-11ef-a816-5f4560c3d1dc.jpg

First Name

Amanda

Last Name

North

NPI

1679625495

Faculty ID

11065

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Amanda North graduated from Princeton University with an A.B. in Religion and a certificate in Latin American Studies. She went on to medical school at the Albert Einstein College of Medicine where she was elected AOA and awarded the Montefiore Staff and Alumni Award at graduation.</p>
<p>She went on to complete a residency in Urology at Montefiore Medical Center. She spent 2 years in Baltimore completing a fellowship in Pediatric Urology was at the Johns Hopkins Hospital. She has been an Assistant Professor of Pediatric Urology at Montefiore Medical Center for the past 5 years. Her professional interests include general pediatric urology with on focus on perinatal issues in urology, including prenatal consultations.<br /><br /></p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Specializes in the care and treatment of children with complex voiding problems and congenital anomalies of the urinary tract.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4270

Biography

<p>Amanda C. North, MD, Professor of Urology, is an expert in Pediatric Urology who specializes in the care and treatment of children with complex voiding problems and congenital anomalies of the urinary tract. Dr. North earned her medical degree from Albert Einstein College of Medicine (Alpha Omega Alpha); she subsequently trained in General Surgery and Urology in the Einstein/Montefiore program . Dr. North completed fellowship training in Pediatric Urology at Johns Hopkins University and joined the faculty of The Department of Urology at Montefiore in 2007.</p><p>Dr. North is the recipient of the Montefiore Staff and Alumni Association Award. Dr. North is a member of the American Urological Association and Society for Pediatric Urology. Dr. North is fluent in Spanish.</p>

Is Open Scheduling

Off

Joel Neugarten

https://assets.montefioreeinstein.org/profiles/images/physphoto/Neugarten_Joel_MD_420x504.jpg

First Name

Joel

Last Name

Neugarten

NPI

1750466520

Faculty ID

1225

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Acute and Chronic Kidney Disease<span style="font-size:10.5pt;font-family:'Arial',sans-serif;color:#5B5B5B;"></span></p>

Research Focus

Dr. Neugarten's main research interest is investigating mechanisms of acute and chronic kidney injury

Elsevier Profile

Selected Publications

<p><ol>
<li>Neugarten J. Estrogen and oxidative stress. Gend Med. Mar;4(1):31-2. 2007.</li>
<li>Silbiger S, Neugarten J. Gender and human renal disease. Gend Med.5: Suppl A:S3-S10. Review</li>
<li>Neugarten J: Estrogen and reactive oxygen species. Gender Med. . 2008</li>
</ol></p>

EMR ID

3415

Biography

Dr. Joel Neugarten is currently Professor of Medicine at the Albert Einstein College of Medicine, Medical Director of the Bedford Park Dialysis Unit, and an Attending Nephrologist at Montefiore Medical Center in the Bronx, New York. He is a graduate of the Albert Einstein College of Medicine and the Brooklyn Law School and completed his post graduate training at Mount Sinai Medical Center in New York and at New York University Medical Center. He previously served as Site Director of the Nephrology Division of Montefiore Medical Center and as President of the New York Society of Nephrology. He is an author of over 100 peer reviewed publications and book chapters dealing with numerous aspects of Nephrology. His major research interests include factors that influence the progression of chronic kidney disease and the management of patients with chronic kidney disease.

Visit Type ID

2541

Is Open Scheduling

On

Tina M. Neade

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/7bb3fcb0-c3cc-11eb-9ea2-7374238588d1.jpg

First Name

Tina

Last Name

Neade

NPI

1538331061

Faculty ID

16814

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Chronic kidney disease, Glomerular disease, End stage renal disease, Kidney stones and Hypertension

Elsevier Profile

EMR ID

52322

Biography

Tina Neade, M.D., is an Assistant Professor of Medicine in the Division of Nephrology at Montefiore Medical Center/ Albert Einstein College of Medicine. She earned her medical degree at Albert Einstein College of Medicine, New York in 2002. She then completed her internal medicine residency at Mount Sinai Hospital in New York in 2005, followed by a nephrology fellowship at Mount Sinai Hospital in 2008. Dr Neade joined the faculty at Montefiore Medical Center in 2017. Dr. Neade is board certified in Internal Medicine and Nephrology.&nbsp;

Visit Type ID

2541

Is Open Scheduling

On